CX801 / Helixmith - LARVOL DELTA

Helixmith retrieves CAR-T technology from Bluebird Bio (Korea Biomedical Review) - “Helixmith said that it has retrieved all CAR-T technology and related rights related to VM801, a chimeric antigen receptor-T (CAR-T) therapy targeting TAG-72 antigen, from Bluebird Bio, a U.S biopharmaceutical company. The company transferred the technology for VM801 to Bluebird Bio in 2015 and granted exclusive right to use CAR-T technology related to TAG-72, frequently expressed in solid cancers such as colorectal cancer, ovarian cancer, and prostate cancer. At the time of technology transfer, Helixmith received a down payment of $1 million from Bluebird Bio.”

Licensing / partnership • Colorectal Cancer • Gastrointestinal Cancer • Genito-urinary Cancer • Gynecologic Cancers • Oncology • Ovarian Cancer • Prostate Cancer • Solid Tumor